Q-Line Biotech IPO Review: The Rs 214 Crore Diagnostics Giant That Kept Climbing After Listing

Quick Answer

Q-Line Biotech IPO is one of the largest SME issues of 2026, and one of its clearest winners so far. The Lucknow based in vitro diagnostics manufacturer raised Rs 214 crore, drew roughly 95 times subscription, and listed on 29 May 2026 at Rs 452, a 31.78% premium over the Rs 343 issue price, almost exactly what the Rs 112 grey market premium had implied. The stock has since climbed to around Rs 566.80, up 65% from issue, valuing the company near Rs 1,322 crore. The two things buyers at this level should understand: FY25 profit actually fell 18% despite a revenue surge before the strong 9M FY26 rebound, and Rs 90 crore of the raise, over 40%, went to repaying debt rather than growth.

Q-Line Biotech IPO Key Details at a Glance

What Does Q-Line Biotech Ltd Do?

Q-Line Biotech, incorporated in 2010 and manufacturing from Amausi, Lucknow, is an in vitro diagnostics (IVD) company, it makes the reagents, test kits, point of care devices, consumables and pathology instruments that medical labs use to test blood, urine and other samples. Its portfolio spans clinical chemistry, haematology, immunodiagnostics, molecular diagnostics and rapid tests.

The import substitution angle. Beyond reagents, Q-Line manufactures indigenous Make in India diagnostic analysers, including the Selectra Pro M and Q-Count 5, with annual capacity of about 1.4 million kits and 1,200 Selectra machines. Its Lucknow facility is ISO 13485 certified and has been audited by CDSCO, state drug authorities and European regulatory agencies, credentials that matter in a market dominated by imported diagnostic equipment. You can follow its live price and post listing updates on the IPO GMP Live homepage.

The distribution machine. The company reaches diagnostic labs, hospitals and medical colleges across roughly 26 states through 283 distributors, 103 sales personnel and 35 service engineers, with 362 permanent employees. Promoter and chairman Saurabh Garg brings over 31 years in diagnostics, alongside co promoters Amita Garg, Ayush Garg, Ajay Kumar Mahanty and Abhay Agrawal.

How Strong Are Q-Line Biotech Financials?

Revenue has compounded impressively. From Rs 206 crore in FY24 to Rs 323 crore in FY25, growth of 56%, with Rs 232 to 237 crore already recorded in just the nine months to December 2025. For an SME listing, this is mainboard scale revenue.

The FY25 profit dip, stated plainly. Despite that revenue surge, net profit fell 18% from Rs 34.44 crore in FY24 to Rs 28.13 crore in FY25, margin compression that Univest flagged as a key pre IPO risk. The encouraging answer came in the nine months of FY26: profit rebounded to Rs 38.69 crore, already exceeding both prior full years, suggesting the FY25 squeeze was a growth investment phase rather than structural decay. The market's willingness to keep re rating the stock after listing rests largely on that rebound holding.

On valuation. At Rs 566.80, the roughly Rs 1,322 crore market cap works out to about 25 to 26 times the annualised 9M FY26 earnings, a full but not absurd multiple for a growing, regulated diagnostics manufacturer with import substitution tailwinds, and well below where pure defence SME winners like Apsis Aerocom now trade.

Why Did the Stock Keep Rising After a Strong Listing?

Several reinforcing factors, and one worth double checking:

• The GMP earned its credibility here. The Rs 112 premium implied a listing near Rs 455, and the stock opened at Rs 452, one of the most accurate grey market calls in our 2026 tracking, alongside Accord Transformer.
• Institutional depth was real. Rs 61.10 crore of anchor money from 18 investors, a Rs 27.44 crore pre IPO placement at the full Rs 343 price, and 124 times QIB subscription gave this issue a professional investor base most SME listings never have.
• The 9M FY26 numbers answered the biggest question. With profit rebounding past both prior years, the market got its evidence that the FY25 margin dip was temporary, fuelling the climb from Rs 452 to Rs 567.
• The healthcare diagnostics theme has structural wind. India's diagnostics market growth, government Make in India procurement preference, and the scarcity of listed IVD manufacturers all support the premium.

Should You Buy Q-Line Biotech Shares Now?

The stock trades around Rs 566.80 against a Rs 343 issue price. The honest read by investor type:

• Conservative investors: This is one of the few SME winners where a watchful entry case exists, real scale, regulatory credentials, institutional ownership, but the 65% run means waiting for a consolidation or the next results is the prudent path rather than chasing.
• Moderate investors: Allottees can hold the core position with confidence the rally is earnings supported, while booking partial profits after a 65% gain is never wrong. The FY26 full year results are the natural checkpoint.
• Aggressive investors: The import substitution story and the profit rebound justify participation on pullbacks, with the margin trajectory as the metric to watch, if the FY25 style compression returns as the company chases growth, the multiple will compress with it.

Honest take. Q-Line Biotech is what a substantive SME IPO looks like: real revenue scale, regulatory moats, genuine institutional participation, and a post listing rally built on published numbers rather than scarcity games. The honest caveats are the FY25 profit dip that preceded the rebound, the Rs 90 crore of investor money that went backward into debt repayment, and the Rs 25.89 crore, about 12% of the raise, consumed by issue expenses. None of these undermine the business, but they are the reasons the entry price you pay matters, at Rs 343 investors were paid for those risks, at Rs 567 they are paying for the recovery already delivered.

Where Did the IPO Money Go?

This was a 100% fresh issue of Rs 214.48 crore, one of the largest SME raises of 2026, with no offer for sale. The allocation split into Rs 93.50 crore for working capital, the genuine need of a distribution heavy diagnostics business financing inventory and receivables across 283 distributors, and Rs 90 crore, about 42% of the raise, for repaying or prepaying borrowings, cleaning up a leveraged balance sheet. Rs 5.10 crore covers general corporate purposes and a substantial Rs 25.89 crore went to issue expenses. The debt repayment share is the structural note for investors: nearly half the money fixed the past rather than funding the future, which makes the company's ability to grow from internal cash flows the thing to watch in coming years.

Contact Details

• Company: Q-Line Biotech Ltd.
• Location: Manufacturing at Amausi, Sarojini Nagar, Lucknow, Uttar Pradesh
• Business: In vitro diagnostics, reagents, kits, POC devices, consumables and indigenous pathology analysers (Selectra Pro M, Q-Count 5), serving labs, hospitals and medical colleges across ~26 states
• Promoters: Saurabh Garg (Chairman and Managing Director), Amita Garg, Ayush Garg, Ajay Kumar Mahanty, Abhay Agrawal
• Registrar: Purva Sharegistry (India) Pvt. Ltd.
• Lead Managers: Hem Securities Ltd., Share India Capital Services Pvt. Ltd.
• Market Maker: Hem Finlease Pvt. Ltd.
• Listing: NSE SME

This page is not investment advice. GMP is indicative only and unofficial. Please consult a SEBI registered financial advisor before investing.